Indaptus director reports 25,000-share ownership

Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock.

Accepted by SEC EDGAR 02/26/2026 - 10:57 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock. He holds 25,000 shares of common stock directly, as shown in this initial statement of beneficial ownership.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider McMurdo Matthew Charles

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 25,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Indaptus Therapeutics (INDP) Form 3 filing show for Matthew Charles McMurdo?

The Form 3 shows that director Matthew Charles McMurdo beneficially owns 25,000 shares of Indaptus Therapeutics common stock. This is an initial ownership report, not a record of a new purchase or sale of shares.

How many Indaptus Therapeutics (INDP) shares does director Matthew Charles McMurdo own?

Director Matthew Charles McMurdo reports owning 25,000 shares of Indaptus Therapeutics common stock. These shares are listed as directly held, reflecting his beneficial ownership position as disclosed in this initial insider ownership report.

Is Matthew Charles McMurdo’s Indaptus (INDP) ownership direct or indirect?

Matthew Charles McMurdo’s reported Indaptus Therapeutics holdings are direct. The filing classifies the 25,000 common shares under direct ownership, with no indication of indirect holding through entities or related parties in the provided data.

Does the Indaptus Therapeutics (INDP) Form 3 indicate any recent insider buying or selling?

The Form 3 does not indicate recent buying or selling. It records an initial statement of beneficial ownership, listing 25,000 directly owned common shares for director Matthew Charles McMurdo without any coded purchase or sale transactions.

What type of security does Matthew Charles McMurdo hold in Indaptus Therapeutics (INDP)?

Matthew Charles McMurdo holds common stock of Indaptus Therapeutics. The report specifies 25,000 shares of common stock as his directly owned position, with no other security types or derivative instruments shown in the provided information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McMurdo Matthew Charles

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC.

3 COLUMBUS CIRCLE 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/26/2026

3. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Matthew McMurdo	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.